Ocular and articular response after RTX therapy
| Case number | Initial perforation | Topical treatment | Systemic treatment other than RTX | Initial BCVA | Final BCVA | Loss of vision | Recurrence | Treatment of recurrence | Ocular inflammation control | Ocular complication | Change of systemic treatment during FUP | Side effect of RTX | Duration of FUP (m) |
| 1 | Yes | DXM+CP+TS | DXC | 20/32 | 20/20 | No | No | – | Yes | – | No | 0 | 27 |
| 2 | No | DXM+TS | DXC | 20/20 | 20/20 | No | No | – | Yes | – | TCZ, baricitinib | 0 | 75 |
| 3 | No | CP+rimexolone+TS | DXC | L: 20/32 R: 20/20 | L: 20/20 R: 20/20 | No | No | – | Yes | Corneal thinning | Baricitinib | 0 | 40 |
| 4 | No | DXM+TS | No | 20/25 | 20/25 | No | No | – | Yes | Ocular hypertension | Stop RTX | 0 | 22 |
| 5 | No | NA | NA | 20/20 | 20/20 | No | 8 m after RTX | Restart RTX | Yes | Corneal thinning/stromal opacities | No | 0 | 32 |
| 6 | Yes | DXM+TS+CP | NA | NA | 20/32 | NA | No | – | Yes | NA | No | 0 | 8 |
| 7 | Yes | DXM+TS+atropine | MTX | 20/63 | NA | NA | No | – | NA | NA | No | 0 | 5 |
BCVA, best-corrected visual acuity; CP, ciclosporine; DXC, doxycycline; DXM, dexamethasone; FUP, follow-up; MTX, methotrexate; NA, not applicable; RTX, rituximab; TCZ, tocilizumab; TS, tear substitue.